Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Avery Hughes

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
MDM Policy & Practice|March 2, 2023
Infliximab Pricing in International Economic Evaluations in Inflammatory Bowel Disease to Inform Biologic and Biosimilar Access Policies: A Systematic ReviewNaazish S Bashir, Avery Hughes, Wendy J Ungar
The Journal of Thoracic and Cardiovascular Surgery|October 20, 2018
Cost and effectiveness: Can't have one without the otherDerrick Y Tam, Avery Hughes, Harindra C Wijeysundera, et al.
The Annals of Thoracic Surgery|May 7, 2018
Cost-Effectiveness of Self-Expandable Transcatheter Aortic Valves in Intermediate-Risk PatientsDerrick Y Tam, Avery Hughes, Harindra C Wijeysundera, et al.
Journal of the Canadian Association of Gastroenterology|March 1, 2021
A Cost-Utility Analysis of Switching from Reference to Biosimilar Infliximab Compared to Maintaining Reference Infliximab in Adult Patients with Crohn's DiseaseAvery Hughes, John K Marshall, Myla E Moretti, et al.
Journal of the Canadian Association of Gastroenterology|June 24, 2021
ErratumAvery Hughes, John K Marshall, Myla E Moretti, et al.
Journal of Medical Economics|January 17, 2022
Clinical and economic benefits of lenzilumab plus standard of care compared with standard of care alone for the treatment of hospitalized patients with COVID-19 in the United States from the hospital perspectiveAdrian Kilcoyne, Edward Jordan, Allen Zhou, et al.
The Journal of Thoracic and Cardiovascular Surgery|February 19, 2018
A cost-utility analysis of transcatheter versus surgical aortic valve replacement for the treatment of aortic stenosis in the population with intermediate surgical riskDerrick Y Tam, Avery Hughes, Stephen E Fremes, et al.
Dermatology and Therapy|September 4, 2025
Network Meta-analysis of 1.5% Ruxolitinib Cream Versus Systemic Agents in the Treatment of Moderate Atopic DermatitisMelinda J Gooderham, H Chih-Ho Hong, Di Wang, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
MDM Policy & Practice|March 2, 2023
Infliximab Pricing in International Economic Evaluations in Inflammatory Bowel Disease to Inform Biologic and Biosimilar Access Policies: A Systematic ReviewNaazish S Bashir, Avery Hughes, Wendy J Ungar
The Journal of Thoracic and Cardiovascular Surgery|October 20, 2018
Cost and effectiveness: Can't have one without the otherDerrick Y Tam, Avery Hughes, Harindra C Wijeysundera, et al.
The Annals of Thoracic Surgery|May 7, 2018
Cost-Effectiveness of Self-Expandable Transcatheter Aortic Valves in Intermediate-Risk PatientsDerrick Y Tam, Avery Hughes, Harindra C Wijeysundera, et al.
Journal of the Canadian Association of Gastroenterology|March 1, 2021
A Cost-Utility Analysis of Switching from Reference to Biosimilar Infliximab Compared to Maintaining Reference Infliximab in Adult Patients with Crohn's DiseaseAvery Hughes, John K Marshall, Myla E Moretti, et al.
Journal of the Canadian Association of Gastroenterology|June 24, 2021
ErratumAvery Hughes, John K Marshall, Myla E Moretti, et al.
Journal of Medical Economics|January 17, 2022
Clinical and economic benefits of lenzilumab plus standard of care compared with standard of care alone for the treatment of hospitalized patients with COVID-19 in the United States from the hospital perspectiveAdrian Kilcoyne, Edward Jordan, Allen Zhou, et al.
The Journal of Thoracic and Cardiovascular Surgery|February 19, 2018
A cost-utility analysis of transcatheter versus surgical aortic valve replacement for the treatment of aortic stenosis in the population with intermediate surgical riskDerrick Y Tam, Avery Hughes, Stephen E Fremes, et al.
Dermatology and Therapy|September 4, 2025
Network Meta-analysis of 1.5% Ruxolitinib Cream Versus Systemic Agents in the Treatment of Moderate Atopic DermatitisMelinda J Gooderham, H Chih-Ho Hong, Di Wang, et al.
Pageof 1